Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1

Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2021-04, Vol.17 (4), p.1223-1234
Main Authors: Skansberg, Annika, Sauer, Molly, Tan, Marissa, Santosham, Mathuram, Jennings, Mary Carol
Format: Article
Language:English
Subjects:
diarrhea
Product Review
Rotavirus
vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753
cites cdi_FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753
container_end_page 1234
container_issue 4
container_start_page 1223
container_title Human vaccines & immunotherapeutics
container_volume 17
creator Skansberg, Annika
Sauer, Molly
Tan, Marissa
Santosham, Mathuram
Jennings, Mary Carol
description Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.
doi_str_mv 10.1080/21645515.2020.1804245
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2020_1804245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a21ac8f6b3d6427aa242c19c2e94da89</doaj_id><sourcerecordid>2456415404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753</originalsourceid><addsrcrecordid>eNp9kVtv1DAQhSMEolXpTwDlkYem-DJOnBfEasVl0aKiUhBv1sSX1lU2LnayVf893ktX9IV58ej4zDcjnaJ4Tck5JZK8Y7QGIag4Z4RlSRJgIJ4Vxxu9EgJ-Pz_0VBwVpyndklwNYVDXL4sjzimjnLXHxdfvMZhJj2W0a2_vy-DK8caWMYy49nFK5Rq19oNN5eXF1ezHYrE823a_ZvOzEgdTXm6dQ_WNvipeOOyTPd2_J8XPTx-v5l-q5cXnxXy2rLTgMFYOoAYuG8k5Q9k1DTBGrXRNTXNJLUTXAkch0TomKTVWEwttJ6AzVjaCnxSLHdcEvFV30a8wPqiAXm2FEK8VxtHr3ipkFLV0dcdNDaxBZMA0bTWzLRiUbWa937Hupm5ljbbDGLF_An36M_gbdR3WShIqecsy4O0eEMOfyaZRrXzStu9xsGFKKudSAxVAIFvFzqpjSClad1hDidrEqh5jVZtY1T7WPPfm3xsPU48hZsOHncEPLsQV3ofYGzXiQx-iizhonxT__46_KcOunA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456415404</pqid></control><display><type>article</type><title>Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1</title><source>PubMed Central(OpenAccess)</source><creator>Skansberg, Annika ; Sauer, Molly ; Tan, Marissa ; Santosham, Mathuram ; Jennings, Mary Carol</creator><creatorcontrib>Skansberg, Annika ; Sauer, Molly ; Tan, Marissa ; Santosham, Mathuram ; Jennings, Mary Carol</creatorcontrib><description>Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2020.1804245</identifier><identifier>PMID: 33121329</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>diarrhea ; Product Review ; Rotavirus ; vaccines</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2021-04, Vol.17 (4), p.1223-1234</ispartof><rights>2020 Taylor &amp; Francis Group, LLC 2020</rights><rights>2020 Taylor &amp; Francis Group, LLC 2020 Taylor &amp; Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753</citedby><cites>FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753</cites><orcidid>0000-0003-1050-7035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018392/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018392/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33121329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skansberg, Annika</creatorcontrib><creatorcontrib>Sauer, Molly</creatorcontrib><creatorcontrib>Tan, Marissa</creatorcontrib><creatorcontrib>Santosham, Mathuram</creatorcontrib><creatorcontrib>Jennings, Mary Carol</creatorcontrib><title>Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.</description><subject>diarrhea</subject><subject>Product Review</subject><subject>Rotavirus</subject><subject>vaccines</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kVtv1DAQhSMEolXpTwDlkYem-DJOnBfEasVl0aKiUhBv1sSX1lU2LnayVf893ktX9IV58ej4zDcjnaJ4Tck5JZK8Y7QGIag4Z4RlSRJgIJ4Vxxu9EgJ-Pz_0VBwVpyndklwNYVDXL4sjzimjnLXHxdfvMZhJj2W0a2_vy-DK8caWMYy49nFK5Rq19oNN5eXF1ezHYrE823a_ZvOzEgdTXm6dQ_WNvipeOOyTPd2_J8XPTx-v5l-q5cXnxXy2rLTgMFYOoAYuG8k5Q9k1DTBGrXRNTXNJLUTXAkch0TomKTVWEwttJ6AzVjaCnxSLHdcEvFV30a8wPqiAXm2FEK8VxtHr3ipkFLV0dcdNDaxBZMA0bTWzLRiUbWa937Hupm5ljbbDGLF_An36M_gbdR3WShIqecsy4O0eEMOfyaZRrXzStu9xsGFKKudSAxVAIFvFzqpjSClad1hDidrEqh5jVZtY1T7WPPfm3xsPU48hZsOHncEPLsQV3ofYGzXiQx-iizhonxT__46_KcOunA</recordid><startdate>20210403</startdate><enddate>20210403</enddate><creator>Skansberg, Annika</creator><creator>Sauer, Molly</creator><creator>Tan, Marissa</creator><creator>Santosham, Mathuram</creator><creator>Jennings, Mary Carol</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1050-7035</orcidid></search><sort><creationdate>20210403</creationdate><title>Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1</title><author>Skansberg, Annika ; Sauer, Molly ; Tan, Marissa ; Santosham, Mathuram ; Jennings, Mary Carol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>diarrhea</topic><topic>Product Review</topic><topic>Rotavirus</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skansberg, Annika</creatorcontrib><creatorcontrib>Sauer, Molly</creatorcontrib><creatorcontrib>Tan, Marissa</creatorcontrib><creatorcontrib>Santosham, Mathuram</creatorcontrib><creatorcontrib>Jennings, Mary Carol</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skansberg, Annika</au><au>Sauer, Molly</au><au>Tan, Marissa</au><au>Santosham, Mathuram</au><au>Jennings, Mary Carol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2021-04-03</date><risdate>2021</risdate><volume>17</volume><issue>4</issue><spage>1223</spage><epage>1234</epage><pages>1223-1234</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>33121329</pmid><doi>10.1080/21645515.2020.1804245</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1050-7035</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2021-04, Vol.17 (4), p.1223-1234
issn 2164-5515
2164-554X
language eng
recordid cdi_crossref_primary_10_1080_21645515_2020_1804245
source PubMed Central(OpenAccess)
subjects diarrhea
Product Review
Rotavirus
vaccines
title Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A35%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Product%20review%20of%20the%20rotavirus%20vaccines%20ROTASIIL,%20ROTAVAC,%20and%20Rotavin-M1&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Skansberg,%20Annika&rft.date=2021-04-03&rft.volume=17&rft.issue=4&rft.spage=1223&rft.epage=1234&rft.pages=1223-1234&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2020.1804245&rft_dat=%3Cproquest_cross%3E2456415404%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-f44643878332a8b774221e8f7611118c55b943a58aef2811dec0e49b54bde8753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2456415404&rft_id=info:pmid/33121329&rfr_iscdi=true